Ovulation induction with human menopausal gonadotropins.
This review has summarized the evolution of hMG stimulation of ovulation in amenorrheic individuals, its monitoring, and its complications. Based on the principles learned from these individuals, use of hMG has now extended to women with cervical mucus deficiencies or luteal phase defects, as well as in vitro fertilization. Recommendations regarding the use of hMG at the current time when assessment by both serum E2 and ultrasound are available have been made. Briefly, it is suggested that an "E2 window" of at least 1000 pg/ml be achieved over the course of a 9- to 12-day follicular phase. Furthermore, assessment of these monitoring modalities should be made in combination in order that findings from one modality alone not be allowed to initiate premature hCG administration.
D000568:Amenorrhea / Q000188:drug therapy / Q000209:etiology; D000818:Animals; D000858:Anovulation / Q000188:drug therapy; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000652:urine; D004971:Estrus; D005260:Female; D006801:Humans; D008596:Menotropins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008991:Monitoring, Physiologic; D010049:Ovarian Diseases / Q000139:chemically induced; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D011272:Pregnancy, Multiple; D013268:Stimulation, Chemical; D014463:Ultrasonography
D006063:Chorionic Gonadotropin; D004967:Estrogens; D004958:Estradiol; D008596:Menotropins